JNJ Stock Chart & Stats
$4609.99
$90.99(2.01%)
―
--
Day’s Range― - ―
52-Week Range$3,105.00 - $4,699.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)241.00
Market Cap
$11.10T
Enterprise Value$620.88K
Total Cash (Recent Filing)$20.76B
Total Debt (Recent Filing)$11.69B
Price to Earnings (P/E)30.4
Beta-0.29
Next Earnings
Oct 20, 2026EPS Estimate
53.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.65
Shares Outstanding2,409,898,700
10 Day Avg. Volume122
30 Day Avg. Volume241
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,888.25Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)204.41
Revenue Forecast (FY)$1.77T
Bulls Say, Bears Say
Bulls Say
Durable High ProfitabilitySustained high gross and operating margins indicate structural pricing power, efficient R&D and manufacturing, and the ability to fund launches, dividends and buybacks. These durable margins support cash conversion and competitive reinvestment across Pharmaceuticals and MedTech over the next 2–6 months and beyond.
Robust Cash Generation & Conservative Balance SheetStrong free cash flow and a large liquidity cushion provide durable financial flexibility to fund pipeline development, M&A (e.g., Firefly Bio), and shareholder returns. Conservative net-debt positioning enhances resilience to cyclical procedure volumes and supports multi-year strategic investments.
Material Pipeline & Strategic Product ApprovalsPhase‑3 efficacy readouts and a De Novo robotic approval represent structural catalysts: strong pivotal oncology data can expand indications and drive sustained sales, while OTTAVA creates a new MedTech platform optionality, underpinning multi-year growth and differentiation in surgical robotics and procedures.
Bears Say
Legacy Franchise Erosion (STELARA)A steep, sustained STELARA decline from biosimilars and class dynamics materially reduces legacy revenue base and requires replacement by new launches. Managing this structural revenue gap will pressure portfolio growth and force heavier reliance on newer, still‑scaling products over the next several quarters.
MedTech Procedural & Competitive PressureSlower cardiovascular procedures, competitive PFA dynamics in electrophysiology, and physician selectivity for Abiomed create persistent headwinds for MedTech revenue and margin mix. These structural demand and competitive issues can depress near‑term device utilization and delay expected MedTech recovery into 2H and beyond.
Earnings & Capital Metric VolatilityMaterial year‑to‑year swings in leverage and reported profitability, combined with higher litigation, restructuring and tax impacts noted on the call, reduce predictability of GAAP results and may constrain capital allocation choices. This variability complicates forecasting cash available for discretionary investments over the medium term.
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $3105.00 and its highest was $4699.99 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $11.10T.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Oct 20, 2026 which is in 87 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jul 15, 2026. The company reported $50.776 earnings per share for the quarter, beating the consensus estimate of $49.988 by $0.788.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson does not currently pay dividends.
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 53.38.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,898,700 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $50.776 in its last earnings report, beating expectations of $49.988. Following the earnings report the stock price went down -2.921%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in MX:JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4,888.25 (― Downside)
$4,888.25 (― Downside)
Blogger Sentiment
Bullish
MX:JNJ Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.25%
12-Months-Change
Fundamentals
Return on Equity
1.97%
Trailing 12-Months
Asset Growth
3.97%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
JNJ Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$4,888.25